vs
Side-by-side financial comparison of ACNB CORP (ACNB) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $47.2M, roughly 2.0× ACNB CORP). Vericel Corp runs the higher net margin — 25.0% vs 22.9%, a 2.1% gap on every dollar of revenue. On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs 23.3%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 22.1%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
ACNB vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $92.9M |
| Net Profit | $10.8M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 27.9% | 24.1% |
| Net Margin | 22.9% | 25.0% |
| Revenue YoY | 42.2% | 23.3% |
| Net Profit YoY | 63.8% | 17.3% |
| EPS (diluted) | $1.10 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | $92.9M | ||
| Q3 25 | $50.9M | $67.5M | ||
| Q2 25 | $50.3M | $63.2M | ||
| Q1 25 | $43.5M | $52.6M | ||
| Q4 24 | $33.2M | $75.4M | ||
| Q3 24 | $34.1M | $57.9M | ||
| Q2 24 | $33.3M | $52.7M | ||
| Q1 24 | $31.6M | $51.3M |
| Q4 25 | $10.8M | $23.2M | ||
| Q3 25 | $14.9M | $5.1M | ||
| Q2 25 | $11.6M | $-553.0K | ||
| Q1 25 | $-272.0K | $-11.2M | ||
| Q4 24 | $6.6M | $19.8M | ||
| Q3 24 | $7.2M | $-901.0K | ||
| Q2 24 | $11.3M | $-4.7M | ||
| Q1 24 | $6.8M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 27.9% | 24.1% | ||
| Q3 25 | 37.2% | 5.1% | ||
| Q2 25 | 29.7% | -3.2% | ||
| Q1 25 | -1.3% | -24.3% | ||
| Q4 24 | 24.8% | 24.5% | ||
| Q3 24 | 27.6% | -4.3% | ||
| Q2 24 | 42.8% | -11.5% | ||
| Q1 24 | 26.9% | -10.7% |
| Q4 25 | 22.9% | 25.0% | ||
| Q3 25 | 29.2% | 7.5% | ||
| Q2 25 | 23.2% | -0.9% | ||
| Q1 25 | -0.6% | -21.4% | ||
| Q4 24 | 19.9% | 26.3% | ||
| Q3 24 | 21.1% | -1.6% | ||
| Q2 24 | 33.9% | -8.9% | ||
| Q1 24 | 21.4% | -7.5% |
| Q4 25 | $1.10 | $0.46 | ||
| Q3 25 | $1.42 | $0.10 | ||
| Q2 25 | $1.11 | $-0.01 | ||
| Q1 25 | $-0.03 | $-0.23 | ||
| Q4 24 | $0.77 | $0.40 | ||
| Q3 24 | $0.84 | $-0.02 | ||
| Q2 24 | $1.32 | $-0.10 | ||
| Q1 24 | $0.80 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $137.5M |
| Total DebtLower is stronger | $255.4M | — |
| Stockholders' EquityBook value | $420.0M | $354.6M |
| Total Assets | $3.2B | $488.0M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | $137.5M | ||
| Q3 25 | $102.1M | $135.4M | ||
| Q2 25 | $103.1M | $116.9M | ||
| Q1 25 | $123.6M | $112.9M | ||
| Q4 24 | $47.3M | $116.2M | ||
| Q3 24 | $58.1M | $101.7M | ||
| Q2 24 | $86.3M | $102.5M | ||
| Q1 24 | $53.1M | $110.6M |
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | — | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | — | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
| Q4 25 | $420.0M | $354.6M | ||
| Q3 25 | $408.6M | $321.9M | ||
| Q2 25 | $395.2M | $306.8M | ||
| Q1 25 | $386.9M | $295.5M | ||
| Q4 24 | $303.3M | $292.0M | ||
| Q3 24 | $306.8M | $257.5M | ||
| Q2 24 | $289.3M | $243.0M | ||
| Q1 24 | $279.9M | $233.9M |
| Q4 25 | $3.2B | $488.0M | ||
| Q3 25 | $3.3B | $453.3M | ||
| Q2 25 | $3.3B | $435.6M | ||
| Q1 25 | $3.3B | $424.6M | ||
| Q4 24 | $2.4B | $432.7M | ||
| Q3 24 | $2.4B | $390.4M | ||
| Q2 24 | $2.5B | $376.8M | ||
| Q1 24 | $2.4B | $356.7M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $15.0M |
| Free Cash FlowOCF − Capex | $52.6M | $12.8M |
| FCF MarginFCF / Revenue | 111.4% | 13.8% |
| Capex IntensityCapex / Revenue | 2.3% | 2.4% |
| Cash ConversionOCF / Net Profit | 4.96× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | $15.0M | ||
| Q3 25 | $23.2M | $22.1M | ||
| Q2 25 | $17.8M | $8.2M | ||
| Q1 25 | $-71.0K | $6.6M | ||
| Q4 24 | $39.8M | $22.2M | ||
| Q3 24 | $13.6M | $10.2M | ||
| Q2 24 | $9.7M | $18.5M | ||
| Q1 24 | $10.8M | $7.2M |
| Q4 25 | $52.6M | $12.8M | ||
| Q3 25 | $22.8M | $19.5M | ||
| Q2 25 | $17.6M | $81.0K | ||
| Q1 25 | $-730.0K | $-7.6M | ||
| Q4 24 | $38.8M | $8.5M | ||
| Q3 24 | $13.3M | $-9.2M | ||
| Q2 24 | $9.4M | $1.8M | ||
| Q1 24 | $10.7M | $-6.8M |
| Q4 25 | 111.4% | 13.8% | ||
| Q3 25 | 44.7% | 28.8% | ||
| Q2 25 | 35.0% | 0.1% | ||
| Q1 25 | -1.7% | -14.5% | ||
| Q4 24 | 117.0% | 11.2% | ||
| Q3 24 | 39.1% | -15.9% | ||
| Q2 24 | 28.3% | 3.4% | ||
| Q1 24 | 33.9% | -13.3% |
| Q4 25 | 2.3% | 2.4% | ||
| Q3 25 | 0.8% | 3.9% | ||
| Q2 25 | 0.4% | 12.9% | ||
| Q1 25 | 1.5% | 27.0% | ||
| Q4 24 | 2.9% | 18.3% | ||
| Q3 24 | 0.7% | 33.5% | ||
| Q2 24 | 0.9% | 31.8% | ||
| Q1 24 | 0.2% | 27.3% |
| Q4 25 | 4.96× | 0.65× | ||
| Q3 25 | 1.56× | 4.35× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | 1.12× | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
